查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930149

全球頭孢菌素市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量因素以及未來預測（2026-2034）

Cephalosporin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 159 Pages | 商品交期: 請詢問到貨日

價格

頭孢菌素市場成長因素

受細菌感染日益增多和廣譜抗生素需求不斷增長的推動，全球頭孢菌素市場呈現穩定成長態勢。 2025年，該市場規模為83.2億美元，預計2026年將成長至87.3億美元，到2034年將達到136.2億美元，預測期內複合年增長率（CAGR）為5.72%。北美地區憑藉其先進的醫療基礎設施和較高的處方量，在2025年佔市場主導地位，市佔率達47.05%。

頭孢菌素類抗生素是β-內酰胺類抗生素，其作用機轉是透過抑制細菌細胞壁合成來殺死細菌。 這些抗生素廣泛用於治療泌尿道感染、呼吸道感染、皮膚和軟組織感染、肺炎和腦膜炎等感染性疾病。抗菌素抗藥性 (AMR) 的持續出現正在加速新一代頭孢菌素類抗生素的研發，這些抗生素對抗藥性菌株具有更高的療效。

市場動態

市場驅動因素

大型製藥公司不斷推出新產品是市場成長的主要驅動因素。抗生素抗藥性的上升迫使各公司加大研發投入，以開發對多重抗藥性細菌有效的先進頭孢菌素類抗生素，例如頭孢洛林和頭孢吡肟。

例如，2024 年 4 月，巴塞爾製藥公司 (Basilea Farmaceutica) 的 Zebutera（頭孢吡肟）獲得美國 FDA 批准，用於治療血流感染、急性細菌性皮膚感染和社區獲得性肺炎。 此類批准將顯著提振市場需求。

市場限制因子

頭孢菌素類抗生素的副作用，特別是胃腸道併發症和過敏反應，正在限制市場成長。此外，有報告指出具有神經毒性，尤其是在老年患者和接受高劑量靜脈給藥的患者中，這引發了人們對安全性的擔憂。

2023年3月，紐西蘭藥物不良反應委員會指出，頭孢菌素類抗生素會引起神經系統副作用，如癲癇發作和腦病，因此建議謹慎用藥，並限制其廣泛應用。

市場機會

藥物遞送系統和奈米顆粒製劑的進步帶來了巨大的成長機會。目前的研究重點是利用金奈米顆粒和銀奈米顆粒將老一代頭孢菌素轉化為奈米抗生素，以提高療效、減少給藥頻率並克服抗藥性。

2023年1月，美國國立衛生研究院 (NIH) 的一項研究表明，利用金奈米顆粒可以將無效的頭孢菌素類抗生素轉化為高效的奈米抗生素，這為市場擴張提供了一條充滿希望​​的途徑。

市場挑戰

強而有力的調控架構對於應對抗菌素抗藥性 (AMR) 構成了一項重大挑戰。世界各國政府都在積極推動抗菌藥物管理計畫的實施，以遏止抗生素的濫用。

例如，2024年10月，印度醫學研究理事會 (ICMR) 報告稱，引起泌尿道感染 (UTI) 的病原體對第三代頭孢菌素的抗藥性很高，這凸顯了處方管理的重要性。

頭孢菌素市場趨勢

一個關鍵的市場趨勢是聯合療法（將頭孢菌素類抗生素與β-內酰胺酶抑制劑聯合使用）的使用日益增多，以提高對抗藥性感染的臨床療效。此外，由於注射劑起效迅速且能標靶給藥，其日益受到青睞，這也影響生產策略。

這一趨勢得到了Sands Active公司於2024年6月在斯里蘭卡投產的注射用頭孢菌素生產廠的支持。

細分市場分析

依代數劃分，第三代頭孢菌素預計將佔領先地位，這得益於其廣譜抗菌活性以及在呼吸道和皮膚感染中的廣泛應用。

依給藥途徑劃分，口服給藥途徑預計將顯著增長，這得益於其使用方便和患者自我治療的增加。同時，受醫院需求的推動，注射給藥途徑也呈現強勁成長。

依疾病劃分，泌尿道感染佔最大佔有率，這主要歸因於醫院獲得性泌尿道感染的增加。

依分銷管道劃分，醫院藥局佔主導地位，這主要得益於其處方量龐大。

區域展望

受醫院獲得性感染率高企的推動，北美預計將引領市場，2025年市場規模將達到38.9億美元，2026年將達到40.9億美元。

由於第二代和第三代頭孢菌素類抗生素的消費量不斷增長，歐洲預計將佔第二大市場。

亞太地區預計將實現最高的複合年增長率，這得益於大規模的原料藥生產和不斷增長的醫療保健投資。

由於監管框架的完善和生產能力的擴大，拉丁美洲以及中東和非洲預計將實現溫和增長。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要公司產品線分析
  • 抗菌藥物治療指引概要
  • 世衛組織抗藥性 "優先病原體" 概要
  • 主要產業動態（併購、合作等）
  • 主要公司新產品發布

第五章 全球市場頭孢菌素市場分析：洞察與預測 (2021-2034)

  • 市場分析、洞察與預測：依代劃分
    • 第一代
    • 第二代
    • 第三代
    • 第四代
    • 其他
  • 市場分析、洞察與預測：依給藥途徑劃分
    • 口服
    • 腸外給藥
  • 市場分析、洞察與預測：依疾病劃分
    • 泌尿道感染
    • 皮膚和軟組織感染
    • 呼吸道感染
    • 腦膜炎
    • 其他
  • 市場分析、洞察與預測：依通路劃分
    • 醫院藥房
    • 零售藥房
    • 線上通路藥房
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第五章 北美頭孢菌素市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲頭孢菌素市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞半島
    • 其他地區歐洲

第八章 亞太地區頭孢菌素市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲頭孢菌素市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章 中東與非洲頭孢菌素市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會 (GCC) 國家
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2025）
  • 公司簡介
    • Pfizer Inc.
    • Sandoz Group AG
    • Merck &Co., Inc.,
    • AbbVie Inc.
    • Bayer AG
    • Astellas Pharma Inc.
    • Shionogi &Co., Ltd
    • Abbott
Product Code: FBI113662

Growth Factors of cephalosporin Market

The global cephalosporin market is demonstrating steady growth, supported by the increasing burden of bacterial infections and the rising demand for broad-spectrum antibiotics. The market was valued at USD 8.32 billion in 2025 and is projected to grow to USD 8.73 billion in 2026, reaching USD 13.62 billion by 2034, registering a CAGR of 5.72% during the forecast period. North America dominated the market with a 47.05% share in 2025, driven by advanced healthcare infrastructure and high prescription volumes.

Cephalosporins are B-lactam antibiotics that inhibit bacterial cell wall synthesis, leading to bacterial cell death. These antibiotics are widely used to treat infections such as urinary tract infections, respiratory infections, skin and soft tissue infections, pneumonia, and meningitis. The continuous emergence of antimicrobial resistance (AMR) has accelerated the development of newer-generation cephalosporins with enhanced efficacy against resistant strains.

Market Dynamics

Market Drivers

The increasing number of new product launches by key pharmaceutical players is a major driver of market growth. Rising antibiotic resistance has compelled companies to invest heavily in R&D to develop advanced cephalosporins such as ceftaroline and ceftobiprole, which are effective against multidrug-resistant bacteria.

For instance, in April 2024, Basilea Pharmaceutica Ltd received U.S. FDA approval for ZEVTERA (ceftobiprole) for bloodstream infections, acute bacterial skin infections, and community-acquired bacterial pneumonia. Such approvals significantly boost market demand.

Market Restraints

The market growth is restrained by adverse effects associated with cephalosporins, including gastrointestinal complications and allergic reactions. Moreover, reports of neurotoxicity, particularly among elderly patients and those receiving high intravenous doses, have raised safety concerns.

In March 2023, New Zealand's Medicines Adverse Reaction Committee highlighted neurological side effects such as seizures and encephalopathy, prompting cautious prescription practices and limiting widespread adoption.

Market Opportunities

Advancements in drug delivery systems and nanoparticle-based formulations present significant growth opportunities. Research studies are focusing on converting older-generation cephalosporins into nano-antibiotics using gold and silver nanoparticles to improve potency, reduce dosage frequency, and overcome resistance.

In January 2023, an NIH study demonstrated that ineffective cephalosporins could be transformed into potent nano-antibiotics using gold nanoparticles, offering a promising avenue for market expansion.

Market Challenges

Strict regulatory frameworks aimed at controlling AMR pose a major challenge. Governments worldwide are enforcing antibiotic stewardship programs to restrict overuse.

For example, in October 2024, the Indian Council of Medical Research (ICMR) reported high resistance levels among UTI-causing pathogens against third-generation cephalosporins, emphasizing the need for controlled prescribing.

Cephalosporin Market Trends

A key market trend is the rising popularity of combination therapies, where cephalosporins are used alongside B-lactamase inhibitors to improve clinical outcomes against resistant infections. Additionally, the growing preference for injectable formulations due to faster action and targeted delivery is shaping production strategies.

In June 2024, Sands Active Ltd. launched a cephalosporin injectable manufacturing plant in Sri Lanka, highlighting this trend.

Segmentation Analysis

By generation, the third-generation cephalosporins segment is expected to dominate due to its broad-spectrum activity and widespread use in respiratory and skin infections.

By route of administration, the oral segment is projected to grow significantly due to ease of use and rising self-medication, while the parenteral segment shows strong growth driven by hospital demand.

By disease indication, urinary tract infections hold the largest share, supported by the rising prevalence of hospital-acquired UTIs.

By distribution channel, hospital pharmacies dominate due to high prescription volumes.

Regional Outlook

North America led the market with a valuation of USD 3.89 billion in 2025 and USD 4.09 billion in 2026, driven by high rates of hospital-acquired infections.

Europe holds the second-largest share due to increased consumption of second- and third-generation cephalosporins.

Asia Pacific is expected to register the highest CAGR, supported by large-scale API production and rising healthcare investments.

Latin America and the Middle East & Africa are anticipated to witness moderate growth owing to improving regulatory frameworks and manufacturing capacity expansion.

Competitive Landscape

The market is semi-consolidated, with key players including Pfizer Inc., Sandoz Group AG, Merck & Co., Inc., AbbVie Inc., GSK plc., Astellas Pharma Inc., and Shionogi & Co., Ltd. These companies focus on R&D investments, strategic collaborations, and capacity expansion to strengthen their market presence.

Conclusion

The global cephalosporin market is expected to grow steadily through 2034, driven by rising bacterial infections, continuous product innovations, and the urgent need to combat antimicrobial resistance. Although adverse effects and strict regulatory controls pose challenges, advancements in combination therapies, nanoparticle-based drug delivery, and injectable formulations are creating new growth opportunities. With North America maintaining dominance and Asia Pacific emerging as a high-growth region, the cephalosporin market is well-positioned for sustained expansion, reinforcing its critical role in modern infectious disease management.

Segmentation

By Generation

  • First Generation
  • Second Generation
  • Third Generation
  • Fourth Generation
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Disease Indications

  • Urinary Tract Infections
  • Skin & Soft Tissue infection
  • Respiratory Infections
  • Meningitis
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
    • U.S.
    • Canada
  • Europe (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Pipeline Analysis, By Key Players
  • 4.2. Overview of Antimicrobial Treatment Guidelines
  • 4.3. Overview of the Antibiotic resistant "Priority Pathogens" Published by WHO
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.5. New Product Launches, By Key Players

5. Global Cephalosporin Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Generation
    • 5.1.1. First Generation
    • 5.1.2. Second Generation
    • 5.1.3. Third Generation
    • 5.1.4. Fourth Generation
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.3.1. Urinary Tract Infections
    • 5.3.2. Skin & Soft Tissue Infections
    • 5.3.3. Respiratory Infections
    • 5.3.4. Meningitis
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacy
    • 5.4.2. Retail Pharmacy
    • 5.4.3. Online Pharmacy
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Cephalosporin Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Generation
    • 6.1.1. First Generation
    • 6.1.2. Second Generation
    • 6.1.3. Third Generation
    • 6.1.4. Fourth Generation
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.3.1. Urinary Tract Infections
    • 6.3.2. Skin & Soft Tissue Infections
    • 6.3.3. Respiratory Infections
    • 6.3.4. Meningitis
    • 6.3.5. Others
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacy
    • 6.4.2. Retail Pharmacy
    • 6.4.3. Online Pharmacy
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Cephalosporin Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Generation
    • 7.1.1. First Generation
    • 7.1.2. Second Generation
    • 7.1.3. Third Generation
    • 7.1.4. Fourth Generation
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.3.1. Urinary Tract Infections
    • 7.3.2. Skin & Soft Tissue Infections
    • 7.3.3. Respiratory Infections
    • 7.3.4. Meningitis
    • 7.3.5. Others
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacy
    • 7.4.2. Retail Pharmacy
    • 7.4.3. Online Pharmacy
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Cephalosporin Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Generation
    • 8.1.1. First Generation
    • 8.1.2. Second Generation
    • 8.1.3. Third Generation
    • 8.1.4. Fourth Generation
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.3.1. Urinary Tract Infections
    • 8.3.2. Skin & Soft Tissue Infections
    • 8.3.3. Respiratory Infections
    • 8.3.4. Meningitis
    • 8.3.5. Others
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacy
    • 8.4.2. Retail Pharmacy
    • 8.4.3. Online Pharmacy
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Cephalosporin Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Generation
    • 9.1.1. First Generation
    • 9.1.2. Second Generation
    • 9.1.3. Third Generation
    • 9.1.4. Fourth Generation
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.3.1. Urinary Tract Infections
    • 9.3.2. Skin & Soft Tissue Infections
    • 9.3.3. Respiratory Infections
    • 9.3.4. Meningitis
    • 9.3.5. Others
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacy
    • 9.4.2. Retail Pharmacy
    • 9.4.3. Online Pharmacy
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Cephalosporin Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Generation
    • 10.1.1. First Generation
    • 10.1.2. Second Generation
    • 10.1.3. Third Generation
    • 10.1.4. Fourth Generation
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.3.1. Urinary Tract Infections
    • 10.3.2. Skin & Soft Tissue Infections
    • 10.3.3. Respiratory Infections
    • 10.3.4. Meningitis
    • 10.3.5. Others
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacy
    • 10.4.2. Retail Pharmacy
    • 10.4.3. Online Pharmacy
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sandoz Group AG
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.,
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. AbbVie Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Bayer AG
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Astellas Pharma Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Shionogi & Co., Ltd
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Abbott
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 2: Global Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 4: Global Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Cephalosporin Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 7: North America Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 8: North America Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 9: North America Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Cephalosporin Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 11: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 12: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 13: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 14: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034
  • Table 16: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 17: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 18: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 19: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034
  • Table 21: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 22: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 23: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 24: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034
  • Table 26: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 27: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 28: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 29: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034

List of Figures

  • Figure 1: Global Cephalosporin Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Cephalosporin Market Value Share (%), by Generation, 2025 & 2034
  • Figure 3: Global Cephalosporin Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Cephalosporin Market Value Share (%), by Disease Indication, 2025 & 2034
  • Figure 5: Global Cephalosporin Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Cephalosporin Market Value Share (%), by Region, 2025 & 2034
  • Figure 7: North America Cephalosporin Market Value (USD billion), by Generation, 2025 & 2034
  • Figure 8: North America Cephalosporin Market Value Share (%), by Generation, 2025
  • Figure 9: North America Cephalosporin Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 10: North America Cephalosporin Market Value Share (%), by Route of Administration, 2025
  • Figure 11: North America Cephalosporin Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 12: North America Cephalosporin Market Value Share (%), by Disease Indication, 2025
  • Figure 13: North America Cephalosporin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Cephalosporin Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Cephalosporin Market Value (USD billion), by Country, 2025 & 2034
  • Figure 16: North America Cephalosporin Market Value Share (%), by Country, 2025
  • Figure 17: Europe Cephalosporin Market Value (USD billion), by Generation, 2025 & 2034
  • Figure 18: Europe Cephalosporin Market Value Share (%), by Generation, 2025
  • Figure 19: Europe Cephalosporin Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 20: Europe Cephalosporin Market Value Share (%), by Route of Administration, 2025
  • Figure 21: Europe Cephalosporin Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 22: Europe Cephalosporin Market Value Share (%), by Disease Indication, 2025
  • Figure 23: Europe Cephalosporin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Cephalosporin Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Cephalosporin Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 26: Europe Cephalosporin Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 27: Asia Pacific Cephalosporin Market Value (USD billion), by Generation, 2025 & 2034
  • Figure 28: Asia Pacific Cephalosporin Market Value Share (%), by Generation, 2025
  • Figure 29: Asia Pacific Cephalosporin Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 30: Asia Pacific Cephalosporin Market Value Share (%), by Route of Administration, 2025
  • Figure 31: Asia Pacific Cephalosporin Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 32: Asia Pacific Cephalosporin Market Value Share (%), by Disease Indication, 2025
  • Figure 33: Asia Pacific Cephalosporin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Cephalosporin Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Cephalosporin Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 36: Asia Pacific Cephalosporin Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 37: Latin America Cephalosporin Market Value (USD billion), by Generation, 2025 & 2034
  • Figure 38: Latin America Cephalosporin Market Value Share (%), by Generation, 2025
  • Figure 39: Latin America Cephalosporin Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 40: Latin America Cephalosporin Market Value Share (%), by Route of Administration, 2025
  • Figure 41: Latin America Cephalosporin Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 42: Latin America Cephalosporin Market Value Share (%), by Disease Indication, 2025
  • Figure 43: Latin America Cephalosporin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Cephalosporin Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Cephalosporin Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 46: Latin America Cephalosporin Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 47: Middle East & Africa Cephalosporin Market Value (USD billion), by Generation, 2025 & 2034
  • Figure 48: Middle East & Africa Cephalosporin Market Value Share (%), by Generation, 2025
  • Figure 49: Middle East & Africa Cephalosporin Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 50: Middle East & Africa Cephalosporin Market Value Share (%), by Route of Administration, 2025
  • Figure 51: Middle East & Africa Cephalosporin Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 52: Middle East & Africa Cephalosporin Market Value Share (%), by Disease Indication, 2025
  • Figure 53: Middle East & Africa Cephalosporin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Cephalosporin Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Cephalosporin Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 56: Middle East & Africa Cephalosporin Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 57: Global Cephalosporin Market Share (%), by Company, 2025